Health Care

Corcept insider Wilson buys 100,000 shares amid earnings miss and regulatory hurdles, signaling cautious confidence in its Cushing’s drug pipeline.

Explore how Addus HomeCare’s insider 10‑b‑5 sales reveal disciplined, tax‑driven trades and what they mean for investor confidence and stock performance.

Discover why United Therapeutics’ leadership is buying and selling shares at strategic times—insider moves reveal confidence in a growing vascular therapy pipeline and solid long‑term upside.

Scavilla’s modest sale of 1,194 shares is a routine tax‑cover move, yet ongoing insider buying and new partnerships signal DENTSPLY SIRONA’s steady growth focus.

Supernus CFO’s 2,500‑share buy after an RSU sale signals confidence, boosting investor optimism amid a volatile, growth‑oriented biotech pipeline.

Beam Therapeutics’ President Giuseppe Ciaramella’s recent trades—buying at $17, selling at $32, and liquidating options—signal confidence, disciplined risk‑management, and a bullish outlook for the gene‑therapy company’s future.

Quantum‑Si insider buy by senior owner Jafri Amir signals renewed confidence amid sales, hinting at a potential shift toward growth and higher valuation.

Tonix insiders buying zero‑cost options shows confidence in future gains; learn how this move signals upside and what it means for investors.

USPH Insider Buying: COO Eric Joseph’s $0 stock grant signals confidence in undervalued stock and potential upside—watch vesting and earnings.

CEO Ming Hsieh’s modest insider sales show confidence in Fulgent Genetics’ growth plans, underscoring long‑term alignment with shareholders.